Patents by Inventor Peter Brünker

Peter Brünker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250043028
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 18, 2024
    Publication date: February 6, 2025
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Patent number: 12202870
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 21, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Publication number: 20240425616
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 9, 2024
    Publication date: December 26, 2024
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Patent number: 12145994
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: November 19, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Alexander Bujotzek, Harald Duerr, Guy Georges, Christian Klein, Stephane Leclair, Moritz Rapp, Eva Carina Sum, Christine Trumpfheller, Pablo Umaña
  • Publication number: 20240376171
    Abstract: The present invention generally relates to novel isolated polypeptides and immunoconjugates and their uses. The polypeptides and immunoconjugates comprise at least one protease recognitions sequence, which is a substrate for matriptase.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Samuele CALABRO, Peter BRUENKER, Linda FAHRNI, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Evelyn SAUER, Pablo UMAÑA, Inja WALDHAUER
  • Patent number: 12139553
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 12, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Peter Bruenker, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Patent number: 12103982
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: October 1, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
  • Publication number: 20240309092
    Abstract: The present invention generally relates to antibodies that bind to CSF1R and CD3, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease, in particular in the treatment of acute myeloid leukemia (AML).
    Type: Application
    Filed: January 24, 2024
    Publication date: September 19, 2024
    Applicants: Hoffmann-La Roche Inc., Klinikum der Universität München
    Inventors: Peter BRUENKER, Adrian GOTTSCHLICH, Christian KLEIN, Sebastian KOBOLD
  • Publication number: 20230416366
    Abstract: The present invention relates to anti-CD3/anti-CD28 bispecific antigen binding molecules and masked protease activated forms thereof, methods for their production, pharmaceutical compositions containing these molecules, and their use as immunomodulators and/or costiumulators in the treatment of a disease, in particular cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Pablo UMAÑA
  • Publication number: 20230416411
    Abstract: The present invention generally relates to bispecific antibodies that bind to CD3 and Folate Receptor 1 (FolR1), e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 15, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Christian KLEIN, Alexander KNAUPP
  • Publication number: 20230340160
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 26, 2023
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Publication number: 20230287145
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Christiane NEUMANN
  • Publication number: 20230227584
    Abstract: The present invention relates to bispecific antibodies comprising a modified C-terminal crossfab fragment that have reduced or no reactivity against preexisting antidrug antibodies.
    Type: Application
    Filed: September 30, 2022
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Ali BRANSI, Peter BRUENKER, Janine FAIGLE, Sabine IMHOF-JUNG, Roland STAACK, Joerg ZIELONKA
  • Patent number: 11639397
    Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 2, 2023
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umana
  • Publication number: 20230119537
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 20, 2023
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Publication number: 20230123178
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules having at least one moiety capable of specific binding to PD1 and a first and a second polypeptide that are linked to each other by a disulfide bond, the first polypeptide having two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and the second polypeptide having a single ectodomain of the same TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Stefan Seeber, Maria Amann, Sandra Grau-Richards, Peter Bruenker, Pablo Umana, Viktor Levitski, Ekkehard Moessner
  • Patent number: 11525007
    Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: December 13, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Frank Herting, Sylvia Herter, Christian Klein, Ekkehard Moessner, Tilman Schlothauer
  • Patent number: 11459404
    Abstract: The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 4, 2022
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • Publication number: 20220275087
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: December 2, 2021
    Publication date: September 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Publication number: 20220267395
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: November 18, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana